D-Pharm Climbs Most in Two Weeks on Deal to Acquire Thrombotech
D-Pharm Ltd. (DPRM) rose the most in more than two weeks after the biopharmaceutical company reached an initial agreement to buy Thrombotech Ltd., which is developing a peptide that improves the efficiency of stroke medication.
To contact the reporter on this story: David Wainer in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.